CONCLUSION
Bacterial vaginosis is a common cause of vaginal discharge in women. Current recommendations for treatment are not very effective, with up to half of women experiencing recurrence. The likelihood of recurrence can result in significant frustration for both patient and clinician. Although recent studies have advanced our understanding of the pathophysiology of BV, further research is needed to develop more effective treatments that reduce recurrence. Addressing modifiable risk factors and considering the use of suppressive and/or probiotic therapy may improve quality of life for women affected by this condition.
REFERENCES
1. Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis. 2013;56(6):777-786.
2. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004: associations with symptoms, sexual behaviors, and reproductive health. Sex Trans Dis. 2007;34(11): 864-869.
3. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey Data. Obstet Gynecol. 2007;109(1):114-120.
4. Bradshaw CS, Morton AN, Garland SM, et al. Evaluation of a point-of-care test, BVBlue, and clinical and laboratory criteria for diagnosis of bacterial vaginosis. J Clin Microbiol. 2005;43(3):1304-1308.
5. Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97.e1-e6.
6. Schwebke JR. Vaginal discharge. In: Klausner JD, Hook EW III, eds. Current Diagnosis & Treatment of Sexually Transmitted Diseases. New York, NY: McGraw-Hill; 2007. http://accessmedicine.mhmedical.com/content.aspx?bookid=369&Sectionid=39914778. Accessed November 11, 2015.
7. Workowski KA, Bolan GA; CDC. Bacterial vaginosis. In: Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):69-72.
8. Hay P. Recurrent bacterial vaginosis. Curr Opin Infect Dis. 2009;22(1): 82-86.
9. Taylor BD, Darville T, Haggerty CL. Does bacterial vaginosis cause pelvic inflammatory disease? Sex Transm Dis. 2013;40(2):117-122.
10. Marrazzo JM, Wiesenfeld HC, Murray PG, et al. Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis. 2006;193(5):617-624.
11. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29(2):297-301.
12. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983; 74(1):14-22.
13. Girerd PH. Bacterial vaginosis workup (2014). http://emedicine.medscape.com/article/254342-workup. Accessed November 11, 2015.
14. Hoffman BL, Schorge JO, Schaffer JI, et al. Gynecologic infection. In: Hoffman BL, Schorge JO, Schaffer JI, et al, eds. Williams Gynecology. 2nd ed. New York, NY: McGraw-Hill; 2012.
15. Hainer BL, Gibson MV. Vaginitis: diagnosis and treatment. Am Fam Physician. 2011;83(7):807-815.
16. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, No. 72: Vaginitis. Obstet Gynecol. 2006;107(5):1195-1206.
17. Workowski KA, Berman S; CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12): 1-110.
18. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect. 2004;80(1):8-11.
19. Cook RL, Redondo-Lopez V, Schmitt C, et al. Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. J Clin Microbiol. 1992;30(4):870-877.
20. Boris J, Påhlson C, Larsson P-G. Six years observation after successful treatment of bacterial vaginosis. Infect Dis Obstetr Gynecol. 1997;5(4): 297-302.
21. Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacterial vaginosis outcomes in women. Sex Transm Dis. 2012;39(10):822-830.
22. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11): 1478-1486.
23. Fethers KA, Fairley CK, Hocking JS, et al. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis. 2008;47(11):1426-1435.
24. Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2007;44(2):213-219.
25. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194(5):1283-1289.
26. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis. 2009;36(11):732-734.
27. Homayouni A, Bastani P, Ziyadi S, et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis. 2014;18(1):79-86.
28. Bilardi JE, Walker S, Temple-Smith M, et al. The burden of bacterial vaginosis: women’s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS ONE. 2013;8(9):e74378.
29. Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect. 2004;80(1):58-62.
30. Klebanoff MA, Nansel TR, Brotman RM, et al. Personal hygienic behaviors and bacterial vaginosis. Sex Transm Dis. 2010;37(2):94-99.
31. Nansel TR, Riggs MA, Yu K-F, et al. The association of psychosocial stress and bacterial vaginosis in a longitudinal cohort. Am J Obstet Gynecol. 2006;194(2):381-386.